Meta-analysis of selective laser trabeculoplasty versus topical medication in the treatment of open-angle glaucoma

Xingyi Li, Wei Wang and Xiulan Zhang

Abstract

Background: The aim of this study was to examine possible differences in clinical outcomes between selective laser trabeculoplasty (SLT) and topical medication in the treatment of open-angle glaucoma.

Methods: Pertinent prospective comparative controlled trials comparing SLT with medication were selected through extensive searches of the PubMed, Embase, Web of Science, Chinese Biomedicine Database, and the Cochrane Controlled Trials Register database from their inception up to March 2014. Efficacy estimates were measured by their weighted mean difference (WMD) to calculate the intraocular pressure reduction (IOPR) from baseline to endpoint and by the odds ratio (OR) to determine success rates.

Results: Five prospective studies, which met the predefined criteria, were included in the meta-analysis. Four studies were randomized clinical trials and one study was a prospective non-randomized clinical trial. There were a total of 492 eyes of 366 patients with open-angle glaucoma. Four studies involving 325 eyes compared SLT with medication in terms of the IOPR. The WMD of the IOPR from the baseline was 0.6 (95 % confidence intervals: −0.24, 1.43) when comparing SLT with medication. No statistical heterogeneity was observed between studies ($\chi^2 = 1.30, P = 0.75, I^2 = 0.0 \%$). All five studies reported success rates, with a pooled OR of 0.84 (95 % confidence intervals: 0.42, 1.68), which was not statistically significant. No statistical heterogeneity was observed between studies ($\chi^2 = 5.98, P = 0.200, I^2 = 33.1 \%$). Subgroup and sensitivity analysis confirmed the high stability of the meta-analysis results.

Conclusions: Both SLT and topical medication demonstrate similar success rates and effectiveness in lowering intraocular pressure in patients with open-angle glaucoma.

Background

Glaucoma is a leading cause of blindness worldwide [1]. It is estimated that more than 60 million people had glaucoma in 2010, 8.4 million of whom are bilaterally blind as a result of the disease. There are 79.6 million people around the world who will have glaucoma by 2020, and 74 % of them will have open-angle glaucoma (OAG) [2]. Lowering the intraocular pressure (IOP) is still the goal of OAG treatment and remains the most effective way to prevent the development and progression of glaucoma. Currently, there are three methods available to achieve this goal: medication, laser treatments, and surgery [3].

Medication therapy is typically the first approach for reducing IOP. Currently, many kinds of potently hypotensive topical medicines are available for controlling IOP [4]. However, medications have potential disadvantages. Patients must tolerate drug side effects, repeated application of drugs and ongoing medical costs [5]. The introduction of selective laser trabeculoplasty (SLT) provided a new non-invasive choice for the reduction of IOP in eyes with OAG [6]. This treatment consists of the application of laser spots in the trabecular meshwork which leads to an increase in the outflow facility and, consequently, decreases IOP.

In a previous Cochrane systematic review on laser trabeculoplasty, only one study comparing SLT with...
medication was included, which prevented the meta-analysis at that time [3]. In a recent meta-analysis comparing SLT with argon laser trabeculoplasty (ALT) in the treatment of OAG, the role of medication also was not evaluated [7]. Thus, the effectiveness of SLT compared to contemporary medication requires further investigation. Recently, McAlinden et al. [8] reviewed the IOP-lowering effect when comparing SLT to other glaucoma treatment options. In that article, the author only described the effects of SLT and did not perform a meta-analysis.

Currently, several published clinical trials have compared the efficacy and safety of SLT with medical therapy [9–13]. For example, Lai et al. [13] reported that the IOP-lowering effect of SLT in Chinese patients is comparable with topical medications. However, these studies had modest sample sizes and conveyed inconclusive results. To date, no consensus has been reached on this topic. Previously, we conducted a meta-analysis comparing SLT with ALT; the results reveal that SLT has similar efficacy to ALT with a similar constellation of side effects [14]. To our knowledge, the data comparing SLT with topical medication in the treatment of OAG has not been systematically evaluated and reported. Therefore, we conducted a systematic review and meta-analysis of all published prospective clinical trials to assess the outcomes of SLT versus medication in the treatment of OAG.

Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used as a guide to conduct the study, including the strategies for searching, analysis, the presentation of results, potential bias, interpretation, and writing (Additional file 1: Table S1) [15].

Literature search and trial selection
Studies were identified and retrieved through a systematic search of PubMed, Embase, the Web of Science, the Chinese Biomedicine Database, and the Cochrane Controlled Trials Register database from their inception up to March 2014. Periodical literature update was performed and the most recent literature retrieving was at June 30, 2015. However, no new original articles comparing SLT to medication was identified. Keywords used in identifying relevant researches included ‘selective laser trabeculoplasty’, ‘Yag laser trabeculoplasty’, ‘selective laser trabeculectomy’, ‘Nd:YAG’, ‘SLT’, ‘glaucoma’, and ‘ocular hypertension’. Searches were performed by combining the keywords or their relevant abbreviations and truncations. No restriction was applied for language or year of publication. The websites of professional associations and Google Scholar were also searched for additional information. Moreover, a manual search was performed by checking the reference lists of all retrieved trials to identify studies not yet included in the computerized databases. Eligible studies were prospective randomized or non-randomized comparative controlled trials, which compared the use of SLT and topical anti-glaucoma medications in adult patients with any form of naïve OAG or ocular hypertension (OHT).

Data extraction and outcome measures
The information on author, age, sex, country, duration, sample size, type of glaucoma, study design, and other outcome data were extracted. The incidence of transient post-laser IOP spikes, sustained IOP elevation, anterior chamber reaction, discomfort, redness, and pain were recorded. For studies with overlaps of population, the latest one were included in the final analysis. Given that the effectiveness of OAG treatment is often assessed by the intraocular pressure reduction (IOPR) and percent of intraocular pressure reduction (IOPR %), the primary efficacy outcomes were the IOPR and IOPR % from the baseline to the end of follow up. The secondary efficacy outcome was the success rate. Success was defined as IOPR ≥ 3 mm Hg and/or IOPR % ≥20 % [7]. The adverse events in each intervention were also reviewed.

Assessment of methodology quality
The Downs and Blacks scale, which could evaluate both randomized and non-randomized studies, were used for assessment of the clinical trials [16]. The system comprises 27 items distributed between five subscales regarding reporting (10 items), external validity (three items), bias (seven items), confounding (six items), and power (one item). Any discrepancy in the qualitative assessment between the two observers was discussed and a consensus was reached. The total score of each trial was expressed as a percentage of the maximum achievable score. Studies’ methodological quality was assessed as excellent, good, fair, or poor when the total score was ≥20, from 15 to 19, from 11 to 14, and ≤10, respectively [17].

Statistical analysis
The intent-to-treat analyses were used in each outcome. Additionally, data was combined using an inverse variance random-effects model regardless of heterogeneity [18]. The weighted mean difference (WMD) was calculated for continuous outcomes while the odds ratio (OR) was estimated for dichotomous outcomes. All results were given with 95 % confidence intervals (CIs). Heterogeneity was checked using Cochran’s Q statistic and the P-value. I² metrics, which quantify heterogeneity irrespective of the number of studies, were also reported [19]. Studies with an I² value of greater than 50 % were considered significant heterogeneity. A P-value of less than 0.05
was considered statistically significant. The statistical analysis was performed using Stata SE 12.0 (Stata Corporation LP, College Station, TX, USA).

Sensitivity analysis and publication bias
We also performed subgroup analysis in terms of the medications used within the medication group. In addition, we investigated the influence of a single study on the overall pooled estimate by omitting one study in each turn. To detect publication biases, we visually examined asymmetry in funnel plots. Furthermore, the Begg’s and Egger’s measures were calculated.

Results
Literature search
The initial search yielded 850 relevant publications, of which 814 were excluded for being duplicates from multiple databases or for various other reasons (unrelated topic, reviews, case reports, or case series) on the basis of the titles and abstracts. The remaining 30 were retrieved for full-text review, and 25 of them were excluded because they were studies comparing SLT with other laser therapies rather than drugs (Additional file 2: Table S2). Hence, a final total of five studies published from 2004–2012 were included in this meta-analysis [9–13]. Fig. 1 provides a flow diagram of the search results.

Characteristics and quality assessment of the included studies
In total, there were 492 eyes from 366 patients included in this meta-analysis; 318 eyes were included in the SLT group and 174 eyes were included in the medication group. The characteristics of the included studies are summarized in Table 1. The age of patients ranged

---

**Fig. 1** The selection flowchart of clinical trials included in this meta-analysis
from 25–82 years. One study was a prospective non-randomized comparative trial [11] and four studies were randomized clinical trials (RCT) [9, 10, 12, 13]. The studies had the following geographic distribution: one in the USA, one in China, one in Canada, and two in the UK. The mean duration of follow-up ranged from 4–60 months. In the studies included in the present meta-analysis, SLT was usually performed at 360° with an average power setting between 0.2 mJ and 1.7 mJ. The mean baseline IOP ranged from 25.0 mmHg to 29.3 mmHg in SLT groups, and from 22.8 mmHg to 29.0 mmHg in medication groups. Our prespecified definition of success was target IOP, but different and heterogeneous definitions were used in studies, such as IOP < 21 mmHg after intervention in one study [13], at least a 20 % IOP reduction from baseline measurement in three studies [10–12], and meet the target IOP in one study [9]. Table 2 shows the quality evaluation of each clinical trial. The Downs and Blacks score for each study exceed 16, which indicate adequate methodological quality.

IOP reduction
Four studies involving 325 eyes compared SLT with medication in terms of the IOPR (Fig. 2). No statistical heterogeneity was observed between studies ($\chi^2=1.30, P = 0.75, I^2 = 0.0 \%$), SLT was found to archive a numerically greater IOPR from baseline to end-point; however, the differences in the IOPR were not all statistically significant (WMD = 0.6, 95 % CI: –0.24, 1.43) (Table 3). We divided the studies into 3 subgroups according medication, and then performed a sensitivity analysis excluding the non-randomized study.

All subgroups showed that SLT was similar to medication in IOPR (Table 3). Four studies reported the IOPR % at follow-up endpoint (Fig. 3). Pooling the results revealed no significant difference between the two groups, with a WMD for the IOPR % comparing SLT with medication of $–1.9\%$ (95 % CI: $–5.00\%, 1.10\%$) (Table 3). When only including the RCTs, the differences in IOPR % were also statistically non-significant (Table 3). Additionally, there was no significant heterogeneity in these analyses. Among the biases in the studies, the unit of analysis issue should be mentioned because there were 492 eyes of 366 patients, which lead to overestimate precision of effect estimates since within-patient correlation is not accounted for.

### Table 1 Characteristics of prospective comparative controlled trials comparing SLT with topical medication

| Author(year) | Design, location | NO. of eyes (SLT/med) | Follow-up | Mean age | Baseline IOP | BCVAC/D | Diagnosis | Definition of success | Degrees of SLT/ Average energy | Medication |
|---------------|------------------|-----------------------|-----------|----------|--------------|---------|-----------|-----------------------|-------------------------------|------------|
| Lai(2004)     | SC,RCT, China    | 29/29                 | 60 m      | 51.9     | 26.8 ± 5.6 /26.2 ± 4.2 | 0.1–1.0/ | POAG, OHT | IOP ≤ 21 mmHg          | 360              | 1.0 ± 0.1 mJ | Topical beta-blocker, pilocarpine, dorzolamide latanoprost as monotherapy or in combination |
| Nagar(2005)   | MC,RCT, UK       | 128/39                | 12 m      | 63       | 29.3/29 NA   | POAG, OHT, PDS, PEX | IOPR% ≥ 20 % | 360/180/90 0.2-1.7 mJ | Latanoprost 0.005 %          |
| McIlraith(2006)| MC,Pro, Canada   | 74/26                 | 12 m      | 62       | 26/24.6 NA   | POAG, OHT, PDS, PEX | OP ≤ 22 mmHg | 180               | Latanoprost 0.005 %          |
| Nagar(2009)   | SC,RCT, UK       | 20/20                 | 4-6 m     | NR       | 26.1 ± 4.0 /22.8 ± 4.5 | NA      | POAG, OHT | IOPR% ≥ 20 %          | 360              | 0.2-1.4 mJ | Latanoprost 0.005 %          |
| Katz(2012)    | MC,RCT, USA      | 67/60                 | 9-12 m    | NR       | 25.0 ± 2.2 /24.5 ± 2.2 | NA      | POAG, PEX, OHT | Arrived target IOP     | 360 followed by 180 0.2-1.2 mJ | Topical prostaglandin analog, β-blocker, brimonidine, carbonic anhydrase inhibitor, in combination |

Abbreviations: SLT = selective laser trabeculoplasty; M/F = male/female; m = month; NA = not available. SC = single center, MC = multi-center, RCT = randomized controlled trial; Pro = prospective non-RCT; intervention = SLT/medication; BCVA = best corrected visual acuity; C/D = cup to disc ratio; POAG = primary open angle glaucoma; OHT = ocular hypertension; PDS = pigment dispersion syndrome; PEX = pseudoexfoliation syndrome

### Table 2 Quality scoring components for five clinical trials included in the meta-analysis

| First Author (year) | Quality score component | Score | Over all | Percentage (%) |
|---------------------|-------------------------|-------|----------|----------------|
| Lai(2004)           | I  1                      | 11    | 24       | 75.00 %        |
| Nagar(2005)         | II 3                      | 11    | 24       | 71.88 %        |
| McIlraith(2006)     | III 4                    | 9     | 19       | 59.38 %        |
| Nagar(2009)         | IV 4                     | 11    | 24       | 71.88 %        |
| Katz(2012)          | V  3                      | 11    | 24       | 71.88 %        |

I = reporting; II = external validity; III = bias (seven items); IV = confounding; V = power
Success rate

Five studies reported the proportions of patients achieving target endpoint IOP at follow-up endpoint; the difference in success rate between the SLT group and the medication group was not statistically significant (pooled OR 0.84, 95% CI: 0.42, 1.68) (Fig. 4). No statistical heterogeneity was observed between studies ($\chi^2 = 5.98, P = 0.200$, $I^2 = 33.1\%$). For the subgroup, including RCTs, the difference in success rate between the SLT group and the medication group was not statistically significant either (OR 0.85, 95% CI: 0.34, 2.11).

Adverse events

Concerning adverse events, three studies reported the types and incidences. However, we did not perform a meta-analysis because there were so few cases. In general, adverse events were transient and minor. Transient post-laser IOP spike in some patients was observed. There were no patients with sustained IOP elevation.

Table 3 Subgroup analysis of IOP reduction from the baseline and success rate comparing SLT with medication

| Group                  | No. of studies | WMD/OR Estimate | Lower | Up  | Test for Heterogeneity $\chi^2$ | $P$ | Test for Overall Effect $Z$ | $P$ |
|------------------------|----------------|-----------------|-------|-----|---------------------------------|-----|---------------------------|-----|
| All                    | 4              | 0.60            | -0.24 | 1.43| 1.30                            | 0.00%| 0.730                     | 1.40| 0.163                     |
| Only RCT               | 3              | 0.86            | -0.19 | 1.90| 0.65                            | 0.00%| 0.723                     | 1.60| 0.110                     |
| Combined medication    | 2              | 0.64            | -0.55 | 1.83| 0.09                            | 0.00%| 0.767                     | 1.05| 0.292                     |
| Latanoprost-only       | 2              | 0.61            | -0.73 | 1.94| 1.20                            | 16.4%| 0.274                     | 0.89| 0.374                     |

IOPR%

| Group                  | No. of studies | WMD/OR Estimate | Lower | Up  | Test for Heterogeneity $\chi^2$ | $P$ | Test for Overall Effect $Z$ | $P$ |
|------------------------|----------------|-----------------|-------|-----|---------------------------------|-----|---------------------------|-----|
| All                    | 4              | -1.90 %         | -5.00 | 1.10| 3.78                            | 20.50%| 0.287                     | 1.23| 0.220                     |
| Only RCT               | 3              | -3.20 %         | -9.10 | 2.70| 3.77                            | 47.00%| 0.152                     | 1.06| 0.290                     |
| Combined medication    | 2              | -0.80 %         | -3.20 | 1.50| 0.00                            | 0.00%| 0.988                     | 0.67| 0.502                     |
| Latanoprost-only       | 2              | -5.10 %         | -13.50| 3.20| 2.45                            | 59.2%| 0.117                     | 1.20| 0.230                     |
| All                    | 5              | 0.84            | 0.42  | 1.68| 5.98                            | 33.1%| 0.200                     | 0.50| 0.621                     |
| Only RCT               | 4              | 0.85            | 0.34  | 2.11| 5.58                            | 49.8%| 0.116                     | 0.35| 0.726                     |
| Combined medication    | 2              | 1.46            | 0.61  | 3.49| 0.23                            | 0.00%| 0.629                     | 0.85| 0.396                     |
| Latanoprost-only       | 3              | 0.57            | 0.23  | 1.38| 2.85                            | 29.9%| 0.240                     | 1.26| 0.209                     |

IOP = intraocular pressure; SLT = selective laser trabeculoplasty; IOPR = intraocular pressure reduction; IOPR% = percent intraocular pressure reduction from baseline; Pro = prospective nonrandomized; RCT = prospective randomized controlled trial; OR = odds ratio.
after SLT. Other common side effects, namely, anterior chamber reaction, discomfort, redness, and pain were also described as transient and without sequelae in all studies.

**Sensitivity analysis and publication bias**

The sensitivity analyses suggested that each study did not significantly influence the global estimation of the IOPR, IOPR %, and success rate (Table 4). Due to the limited number (<10) of studies included in each analysis, publication bias was not assessed. Table 5 summarized the overall evidence of SLT versus medicine in the treatment of OAG.

**Discussion**

Introduced in 1995 by Park and Latina [20], SLT provided a new choice for the reduction of IOP in eyes with OAG. SLT is easy to perform and well tolerated by patients. However, the efficacy and safety of SLT versus topical medications for OAG remain unclear. In the preliminary published studies, SLT was used as an adjunct therapy to medication [21]. Later, several studies

---

**Fig. 3** Comparison of percent intraocular pressure reduction from the baseline between SLT group and topical medication group. WMDs indicate weighted mean difference, which were computed by using a random-effects model.

**Fig. 4** Comparison of success rates between SLT group and topical medication group. ORs indicate odds ratios, which were computed by using a random-effects model.
suggested that SLT may serve as the primary therapy for OAG [22–26]. Comparisons of SLT and medication were done in the remaining trials, but there is still not enough evidence to determine which is the best choice [8].

In this meta-analysis, we reviewed five prospective comparative controlled trials. The results reveal that SLT is as effective as medication in regard to the control of IOP, which is consistent with a previous review [8]. In addition, SLT and medication are similar in their success rates. The results from our subgroup and sensitivity analyses were quite similar and robust.

The exact mechanisms of SLT lowering IOP are not known. There are three prevailing theories, namely, the mechanical theory, the biologic theory, and the cell theory [27, 28]. According to the mechanical theory, contraction and shrinkage of trabecular beams caused by SLT exerts a pull on surrounding beams, which opens up the intertrabecular spaces. The biologic theory proposes that laser energy causes tissue injury with a resultant cascade of events. Macrophages are attracted and alter the secreted extracellular matrix, allowing an increased aqueous outflow. The cellular theory suggests that SLT applications stimulate cell division in the anterior trabecular meshwork, providing pluripotent cells for the repopulation of sites with laser therapy. These cells produce different extracellular matrices, enhancing the aqueous outflow. Additionally, there may be other mechanisms of action of SLT. It has been reported that exposure to factors secreted by lasered Schlemm canal cells and lasered trabecular meshwork cells and the application of prostaglandin analogs induced junction disassembly while increasing the permeability of Schlemm canal cells [29]. Recently, Chen et al. [30] determined the effect of travoprost (a drug similar to latanoprost) on Schlemm’s canal in healthy human eyes using fourier-domain optical coherence tomography. They observed that travoprost induced the expansion of Schlemm’s canal lumen. These findings suggest that SLT and latanoprost might share a common mechanism that likely mediated their similar IOP lowering effects.

The results of this meta-analysis must be interpreted cautiously in light of the strengths and limitations of the included trials. A key strength is the fact that all the studies included in this meta-analysis were published by established researchers who adhered to strict methodology guidelines. However, there are some limitations to consider, such as the small sample size and the potential for bias in the selection of trials.

### Table 4 Results of leave-one-out sensitivity analyses

| Study Excluded | Pooled WMD/OR Estimate | Pooled WMD/OR Lower | Pooled WMD/OR Up | χ² | I² | P | Test for Heterogeneity | Test for Overall Effect |
|----------------|------------------------|---------------------|------------------|----|----|--|------------------------|------------------------|
| IOPR           |                        |                     |                  |    |    |   |                        |                        |
| Lai(2004)      | 0.62                   | −0.237              | 1.48             | 1.22 | 0.00 % | 0.542 | 1.42 | 0.156 |
| McIlraith(2006)| 0.86                   | −0.193              | 1.90             | 0.65 | 0.00 % | 0.723 | 1.60 | 0.110 |
| Nagar(2009)    | 0.43                   | −0.48               | 1.33             | 0.37 | 0.00 % | 0.829 | 0.93 | 0.353 |
| Katz(2012)     | 0.51                   | −0.61               | 1.64             | 1.25 | 0.00 % | 0.536 | 0.89 | 0.371 |
| IOPR%          |                        |                     |                  |    |    |   |                        |                        |
| Lai(2004)      | −2.50 %                | −6.60 %             | 1.60 %           | 3.77 | 46.90 % | 0.152 | 1.18 | 0.237 |
| McIlraith(2006)| −3.20 %                | −9.10 %             | 2.70 %           | 3.77 | 47.00 % | 0.152 | 1.06 | 0.290 |
| Nagar(2009)    | −0.90 %                | −3.10 %             | 1.30 %           | 0.06 | 0.00 % | 0.970 | 0.83 | 0.408 |
| Katz(2012)     | −3.90 %                | −9.60 %             | 1.70 %           | 2.65 | 24.40 % | 0.266 | 1.37 | 0.170 |
| Success rate   |                        |                     |                  |    |    |   |                        |                        |
| Lai(2004)      | 0.68                   | 0.33                | 1.43             | 4.02 | 25.4 % | 0.259 | 1.01 | 0.311 |
| Nagar(2005)    | 1.20                   | 0.63                | 2.29             | 0.74 | 0.00 % | 0.864 | 0.54 | 0.588 |
| McIlraith(2006)| 0.85                   | 0.34                | 2.11             | 5.98 | 49.8 % | 0.113 | 0.35 | 0.726 |
| Nagar(2009)    | 0.81                   | 0.35                | 1.87             | 5.83 | 48.6 % | 0.120 | 0.50 | 0.620 |
| Katz(2012)     | 0.78                   | 0.33                | 1.85             | 5.53 | 45.7 % | 0.137 | 0.57 | 0.568 |

CI = confidence interval; IOPR = intraocular pressure reduction; IOPR% = percent intraocular pressure reduction from baseline

### Table 5 Summary of finding table of the overall quality of evidence according to GRADE

| Outcomes     | Eye (Study) | SLT Med | Absolute effect (95% CI) | Relative effect (95% CI) | Quality of evidence | Recommend |
|--------------|-------------|---------|--------------------------|--------------------------|---------------------|-----------|
| IOPR         | 325(4)      | 190     | 135                      | 0.60 (−0.24, 1.43)       | B                   | Low       |
| IOPR%        | 325(4)      | 190     | 135                      | −1.90 % (−5.00 %, 1.10 %) | B                   | Low       |
| Success rate | 298(4)      | 175     | 123                      | 0.84 (0.42, 1.68)        | C                   | Low       |
centers of excellence using a prospective comparative controlled design and all of them were well-performed and of high quality. Despite our rigorous methodology, some limitations of the current study should not be ignored. First, we cannot fully exclude publication bias. The number of included studies is insufficient to carry out statistical testing to detect publication bias. In addition, we did not attempt to gain access to unpublished results. Second, our analyses of IOPR, IOPR %, and success rate were based on data pooled from trials of different durations. This was due to the lack of data reported in all phases of follow-up and may have a potential impact on our results. Third, when discussing treatment result, it is important to realize that the criteria used to define success varies between studies. Differences between studies may also exist with respect to the diagnostic criteria for glaucoma and the severity of the disease. Fourth, none of the identified studies provided a cost-effectiveness analysis; thus, a prospective randomized clinical trial comparing the cost of SLT to medication is required. The effects of SLT on other outcome measures such as delaying the need for surgery in people with early glaucoma were not assessed. This may be an interesting focus for future studies.

Conclusions
In conclusion, the present meta-analysis suggests that SLT appears to be similar to medication in lowering intraocular pressures in patients with open angle glaucoma. Despite our rigorous methodology, the inherent limitations of the included studies should be considered, and conclusions drawn from our pooled results should be interpreted with caution. Future large-volume, well-designed RCTs with extensive follow-up are awaited to confirm and update the findings of this analysis.

Additional files

Additional file 1: Table S1. PRISMA Checklist. (DOC 69 kb)
Additional file 2: Table S2. The studies were excluded after full-text review. (DOCX 25 kb)

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
All authors conceived of and designed the experimental protocol. XL and WW collected the data. All authors were involved in the analysis. XL wrote the first draft of the manuscript. XL, WW and XZ reviewed and revised the manuscript and produced the final version. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the Science and Technology Program of Guangdong Province, China (2013B020400003) and the Science and Technology Program of Guangzhou, China (15570001).

Received: 27 February 2015 Accepted: 28 July 2015
Published online: 19 August 2015

References
1. Quigley HA. Glaucoma. Lancet. 2011;377:1367–77.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7.
3. Rolim DMC, Paranhos AJ, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev. 2007;AD33919.
4. Realmi T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology. 2002;109:1955–6.
5. Orme M, Collins S, Dakin H, Kelly S, Loftus J. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010;26:511–28.
6. Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, et al. Laser trabeculoplasty for open-angle glaucoma; a report by the american academy of ophthalmology. Ophthalmology. 2011;118:2296–302.
7. Wang H, Cheng JW, Wei RL, Cai JP, Li Y, Ma XY. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. Can J Ophthalmol. 2013;48:186–92.
8. McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye (Lond). 2014;28:249–58.
9. Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma. 2012;21:460–6.
10. Nagar M, Luhishi E, Shah N. Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. Br J Ophthalmol. 2009;93:497–501.
11. McIlraith I, Strasfeld M, Coley V, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma. 2006;15:124–30.
12. Nagar M, Ogunyomade O, O’Brart DP, Hower F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89:1413–7.
13. Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol. 2004;32:368–72.
14. Wang WH, He M, Zhou M, Zhang X. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2013;8:e84270.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.
16. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84.
17. Naylor K, Ward J, Polite BN. Interventions to improve care related to colorectal cancer among racial and ethnic minorities: a systematic review. J Gen Intern Med. 2011;27:1033–46.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
20. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60:359–71.
21. Graener T. Intraocular pressure response of capsular glaucoma and primary open-angle glaucoma to selective Nd:YAG laser trabeculoplasty: a prospective, comparative clinical trial. Eur J Ophthalmol. 2002;12:287–92.
22. Hodge WG, Damji KF, Rock W, Buhrmann R, Bovell AM, Pan Y. Baseline IOP and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010;26:511–28.
23. Juzych MS, Chopra V, Banitt MR, Hughes BA, Kim C, Goulas MT, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology. 2002;109:1955–6.
24. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Matilla M, Macias JM, Benitez-del-Castillo JM, et al. Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain. Eye (Lond). 2004;18:498–502.
25. Damji KF, Shah KC, Rock WJ, Bains HS, Hodge WG. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999;83:718–22.
26. Hollo G. Argon and low energy, pulsed Nd:YAG laser trabeculoplasty. A prospective, comparative clinical and morphological study. Acta Ophthalmol Scand. 1996;74:126–31.
27. Kagan DB, Gorfinkel NS, Hutnik CM. Mechanisms of selective laser trabeculoplasty - review. Clin Experiment Ophthalmol. 2013;42:675–81.
28. Stein JD, Challa P. Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty. Curr Opin Ophthalmol. 2007;18:140–5.
29. Grcar R, Drnovsek-Olup B. Effects of laser beam modification on the anterior chamber angle structural changes after selective laser trabeculoplasty in animal model. Laser Surg Med. 2011;43:910–1.
30. Chen J, Huang H, Zhang S, Chen X, Sun X. Expansion of Schlemm's canal by travoprost in healthy subjects determined by Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54:1127–34.